Bradmer announces Dr. Phil Gold to join Board of Directors
Bradmer Pharmaceuticals Inc., a biopharmaceutical company dedicated to the development and commercialization of cancer therapies, announced that Phil gold, C.C., O.Q., M.D., Ph.D., has agreed to join the Company's Board of Directors effective immediately. Dr. Gold is a pioneer in the study of oncology and physiology with over 40 years of experience in clinical and academic settings. His early research led to the discovery and definition of the Carcinoembryonic Antigen (CEA), the blood test most frequently used in the diagnosis and management of patients with cancer.
Dr. Gold is currently the Executive Director of the Clinical Research Centre of the McGill University Health Centre. He has also served as Chairman of the Department of Medicine at McGill and Physician-in-Chief at the Montreal General Hospital. Dr. Gold has been elected to numerous professional organizations including the American Society for Clinical Investigation, the Association of American Physicians, and Mastership in the American College of Physicians. He has been the recipient of a number of awards including his appointment as a Companion of the Order of Canada and the Robert Taylor Gold Medal from the National Cancer Institute of Canada. Dr. Gold is a graduate of McGill University where he completed his B.Sc. and M.Sc. in physiology and where he later completed his MDCM and Ph.D. In 2006, the Phil Gold Chair in Medicine was inaugurated at McGill University. Dr. Gold will be replacing Mr. Doug Janzen, President and Chief Business Officer of Cardiome Pharma Corp. on the Board of Bradmer.
Other news from the department people
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.
